Back to top

Analyst Blog

Orthopedic implants and instruments maker Symmetry Medical (SMA - Analyst Report) announced the break-out of a fire in its Sheffield, U.K.-based manufacturing facility on Sep 13. The plant produces about 30% of the company’s global implant capacity. The company plans to report the financial impact of the fire in its third-quarter 2013 results after further scrutiny of the situation.

Management reported that the fire had damaged only the Acid Shop and no other operations had been affected. Fortunately, no casualties were reported among the 250 employees working in the plant.

The Acid Shop is used to remove materials from the forging process through acidic baths, and hence operates in conjunction with the forging unit at the Sheffield plant. However, gas, electric, and water utilities serving the casting and forging areas of the plant have been temporarily discontinued as a measure of precaution. Management hopes to restore services to the undamaged portion of the plant within a week.

In an effort to minimize customer disruptions, Symmetry has deployed its Business Continuity Plan to ensure restoration of smooth activity in the rest of the plant. Management has also informed their customers regarding the unfortunate breach in timely delivery of orders. Meanwhile, they expect SMA’s other global manufacturing facilities to replace the functions of the impacted Acid Shop.

Symmetry has a Zacks Rank #4 (Sell). Although the company managed to beat the Zacks Consensus Estimates on both fronts, both its revenues and earnings failed to achieve growth in the second quarter of 2013. The sudden turn of events in the high-margin Surgical business from the beginning of 2013 is a cause of concern. The company needs to resolve integration-related issues of its latest acquisitions to avoid wastage of resources.

While we choose to avoid SMA until we see clear signs of improvement in the underlying business, other medical products companies that warrant a look include Alere (ALR - Snapshot Report), carrying a Zacks Rank #1 (Strong Buy), and Boston Scientific (BSX - Analyst Report) and Exactech (EXAC - Snapshot Report), both carrying a Zacks Rank #2 (Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UTD THERAPE… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%
STRATTEC SE… STRT 80.24 +3.00%